{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T17:00:35Z","timestamp":1767114035892,"version":"3.48.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.endien.2025.501630","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:20:36Z","timestamp":1765977636000},"page":"501630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pembrolizumab-induced dual endocrine disruption: A case report"],"prefix":"10.1016","volume":"72","author":[{"given":"Mar\u00eda Carmen","family":"Dameto Pons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Gonz\u00e1lez Arn\u00e1iz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Antequera Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier F.","family":"P\u00e9rez Candel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Ariadel Cobo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Casta\u00f1\u00f3n Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda D.","family":"Ballesteros Pomar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.endien.2025.501630_bib0060","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cpt.2023.11.005","article-title":"Common endocrine system adverse events associated with immune checkpoint inhibitors","volume":"2","author":"Li","year":"2023","journal-title":"Cancer Pathog Ther"},{"key":"10.1016\/j.endien.2025.501630_bib0065","doi-asserted-by":"crossref","first-page":"212","DOI":"10.7861\/clinmed.2020-0827","article-title":"Endocrine complications of immunotherapies: a review","volume":"21","author":"Hattersley","year":"2021","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.endien.2025.501630_bib0115","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1530\/EC-20-0489","article-title":"Endocrine toxicity of cancer immunotherapy: clinical challenges","volume":"10","author":"Anderson","year":"2021","journal-title":"Endocr Connect"},{"key":"10.1016\/j.endien.2025.501630_bib0120","first-page":"6175","volume":"28","author":"Cooksley","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.endien.2025.501630_bib0080","article-title":"New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer","volume":"2022","author":"Cunha","year":"2022","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.endien.2025.501630_bib0085","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endien.2025.501630_bib0090","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1089\/thy.2021.0685","article-title":"Optimal thyroid hormone replacement dose in immune checkpoint inhibitor-associated hypothyroidism is distinct from Hashimoto's thyroiditis","volume":"32","author":"Mosaferi","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.endien.2025.501630_bib0095","doi-asserted-by":"crossref","first-page":"110414","DOI":"10.1016\/j.intimp.2023.110414","article-title":"Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus","volume":"122","author":"Liao","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.endien.2025.501630_bib0100","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/apjon.apjon_3_19","article-title":"Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a minireview of current clinical guidelines","volume":"6","author":"Trinh","year":"2019","journal-title":"Asia Pac J Oncol Nurs"},{"key":"10.1016\/j.endien.2025.501630_bib0105","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.endien.2025.501630_bib0110","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018025001386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018025001386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T16:57:13Z","timestamp":1767113833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530018025001386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":11,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2530018025001386"],"URL":"https:\/\/doi.org\/10.1016\/j.endien.2025.501630","relation":{},"ISSN":["2530-0180"],"issn-type":[{"type":"print","value":"2530-0180"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab-induced dual endocrine disruption: A case report","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endien.2025.501630","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 SEEN and SED. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"501630"}}